Core Viewpoint - Jiuzhou Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 41.44% but a recent decline of 5.71% over the past five trading days [1] Financial Performance - For the period of January to September 2025, Jiuzhou Pharmaceutical achieved a revenue of 4.16 billion yuan, representing a year-on-year growth of 4.92%. The net profit attributable to shareholders was 748 million yuan, reflecting an 18.51% increase compared to the previous year [2] Stock Market Activity - As of October 23, Jiuzhou Pharmaceutical's stock price was 18.65 yuan per share, with a market capitalization of 16.588 billion yuan. The stock saw a net outflow of 10.89 million yuan in principal funds, with significant selling pressure from large orders [1] - The company has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 51.1 million yuan on April 15 [1] Shareholder Information - As of September 30, 2025, Jiuzhou Pharmaceutical had 59,200 shareholders, an increase of 10.22% from the previous period. The average number of circulating shares per shareholder decreased by 9.27% to 15,035 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several mutual funds, with notable increases in holdings for some [3] Dividend Distribution - Since its A-share listing, Jiuzhou Pharmaceutical has distributed a total of 2.183 billion yuan in dividends, with 1.245 billion yuan distributed over the past three years [3]

Core Viewpoint - The Social Security Fund's investment movements in the third quarter reveal a strategic shift, with notable changes in holdings across various stocks, indicating potential investment opportunities and sector performance trends [1][2][3][4] Group 1: Holdings Overview - The Social Security Fund appeared in the top ten shareholders of 33 stocks by the end of the third quarter, holding a total of 625 million shares valued at 13.07 billion yuan [1] - The fund maintained its position in 6 stocks, initiated positions in 7 stocks, increased holdings in 10 stocks, and reduced holdings in 10 stocks during the quarter [1] - The stock with the highest number of Social Security Fund shareholders is Sanhe Tree, with three funds listed among the top ten shareholders, holding a total of 15.02 million shares, accounting for 2.04% of the company's circulating shares [1] Group 2: Significant Holdings - The stocks with over 10 million shares held by the Social Security Fund include 17 stocks, with Poly Development having the largest holding of 124 million shares, which increased by 19.86 million shares in the third quarter [2] - China Jushi and CNOOC Development follow with holdings of 85.52 million shares and 55.16 million shares, respectively [2] - The highest holding percentage is in Baiya Shares, at 4.34% of circulating shares, with two funds increasing their holdings by over 3.18 million shares [2] Group 3: Market Performance - The newly acquired stocks by the Social Security Fund have seen an average increase of 0.28% since October, with Jinling Mining leading with a 10.36% increase [3] - Other notable performers include Koyuan Wisdom and Blue Science High-tech, with increases of 7.18% and 6.04%, respectively [3] - Among the new stocks, six reported year-on-year net profit growth, with Blue Science High-tech turning a profit with a net profit of 33.31 million yuan [3] Group 4: Performance of Increased Holdings - Among the stocks where the Social Security Fund increased its holdings, nine reported year-on-year net profit growth, with Xinqiang Lian turning a profit with a total revenue of 3.618 billion yuan, up 84.10% year-on-year [4] - The profit growth for Xinqiang Lian is attributed to the recovery in wind power demand and improved cost management [4] - Other companies with significant profit growth include Sanhe Tree, Stanley, Jiuzhou Pharmaceutical, Weili Medical, and Haida Group [4]

Market Overview - The medical services sector experienced a decline of 0.9% on October 22, with Sanbo Brain Science leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the medical services sector included: - Yaokang Biological (688046) with a closing price of 17.18, up 2.81% [1] - Aoyang Health (002172) with a closing price of 4.26, up 1.91% [1] - Haochen Medical (002622) with a closing price of 3.32, up 1.84% [1] - Significant decliners included: - Sanbo Brain Science (301293) with a closing price of 57.19, down 4.67% [2] - Chengda Pharmaceutical (301201) with a closing price of 33.98, down 4.50% [2] - XD Haoyuan Medical (688131) with a closing price of 79.90, down 2.07% [2] Capital Flow - The medical services sector saw a net outflow of 615 million yuan from institutional investors, while retail investors contributed a net inflow of 370 million yuan [2][3] - Key stocks with notable capital flows included: - Kanglong Chemical (300759) with a net inflow of 46.59 million yuan from institutional investors [3] - Aoyang Health (002172) with a net inflow of 10.44 million yuan from institutional investors [3] - Yaokang Biological (688046) with a net inflow of 9 million yuan from institutional investors [3]

Core Viewpoint - Jiuzhou Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 43.64% but a recent decline of 8.63% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Jiuzhou Pharmaceutical achieved a revenue of 4.16 billion yuan, representing a year-on-year growth of 4.92% [2] - The net profit attributable to shareholders for the same period was 748 million yuan, reflecting an 18.51% increase year-on-year [2] Stock Market Activity - As of October 22, Jiuzhou Pharmaceutical's stock price was 18.94 yuan per share, with a market capitalization of 16.846 billion yuan [1] - The stock has seen a net outflow of 33.85 million yuan in principal funds, with significant selling pressure observed [1] Shareholder Information - As of September 30, 2025, the number of Jiuzhou Pharmaceutical's shareholders increased by 10.22% to 59,200 [2] - The average number of circulating shares per shareholder decreased by 9.27% to 15,035 shares [2] Dividend Distribution - Jiuzhou Pharmaceutical has distributed a total of 2.183 billion yuan in dividends since its A-share listing, with 1.245 billion yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 20.368 million shares, an increase of 7.8125 million shares from the previous period [3] - The top ten circulating shareholders include various funds, indicating a diverse institutional interest in the company [3]

Core Viewpoint - The company reported a positive performance in Q3 2025, with revenue and net profit showing significant year-over-year growth, indicating a sustained upward trend in its financial performance [4][5]. Financial Performance - In Q3 2025, the company achieved revenue of 12.90 billion (CNY) (+7.37% YOY) and a net profit of 2.22 billion (CNY) (+42.30% YOY), with a non-GAAP net profit of 2.20 billion (CNY) (+46.42% YOY) [5]. - The gross margin for Q3 2025 was 37.78% (+4.10 percentage points YOY), and the net profit margin was 17.22% (+4.13 percentage points YOY), reflecting a significant improvement in profitability [5]. CDMO Business - The CDMO business generated revenue of 22.91 billion (CNY) in H1 2025 (+16.27% YOY) with a gross margin of 41.02% (-0.04 percentage points YOY) [6]. - The company is deepening collaborations with major clients, with a notable increase in non-commercial projects from overseas core clients and a rapid growth in projects from Biotech clients in the U.S. and Europe [6]. - New orders in Q3 2025 showed a significant recovery, with an increase in key clinical batches and NDA projects, indicating a positive outlook for revenue growth in the next 1-2 years [6]. Emerging Business - The TIDES business is accelerating, with a rapid increase in new peptide projects signed overseas [7]. - The second phase of commercial capacity construction is expected to be operational by November 2025, reaching a scale of 800 kilograms per year, which will alleviate capacity bottlenecks in peptide production [7]. - The company is also establishing commercialization capacity for small nucleic acids domestically while maintaining R&D platforms internationally [7]. API Business - In H1 2025, the API business generated revenue of 5.23 billion (CNY) (-28.48% YOY) with a gross margin of 23.26% (+2.07 percentage points YOY) [9]. - In Q3 2025, prices for certain raw materials showed a slight decline, but the company anticipates an improvement in prices by Q4 2025 [9].

- The provided content does not include any specific quantitative models or factors, their construction methodology, detailed construction process, evaluations, or backtesting results[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38]

请将手机调至振动或无声 浙江九洲药业股份有限公司 2025 年第一次临时股东大会 会 议 资 料 中国·浙江·台州 二〇二五年十月三十一日 1 浙江九洲药业股份有限公司 2025 年第一次临时股东大会会议资料 目 录 | 2025 | 年第一次临时股东大会会议议程 3 | | --- | --- | | 2025 | 年第一次临时股东大会会议须知 5 | | | 股东大会会议议案 7 | | 议案一 | 关于取消监事会并修订《公司章程》的议案…………………………….7 | | 议案二 | 关于制定、修订公司部分管理制度的议案……………………………….8 | 会议召集人：公司董事会 —签到、宣布会议开始— 2 浙江九洲药业股份有限公司 2025 年第一次临时股东大会会议资料 浙江九洲药业股份有限公司 2025 年第一次临时股东大会会议议程 会议时间：2025 年 10 月 31 日下午 14:00 会议地点：浙江九洲药业股份有限公司会议室（浙江省台州市椒江区外沙路 99 号） 1、与会人员签到，领取会议资料；股东及股东代理人同时递交身份证明材 料（授权委托书、营业执照复印件、身份证复印件等）并领取《表决票》 — ...

Core Insights - On October 20, Jiuzhou Pharmaceutical experienced a slight decline of 0.05% with a trading volume of 444 million yuan, indicating a stable market presence [1] - As of September 30, Jiuzhou Pharmaceutical reported a revenue of 4.16 billion yuan for the first nine months of 2025, reflecting a year-on-year growth of 4.92%, and a net profit of 748 million yuan, which is an 18.51% increase compared to the previous year [2] - The company has distributed a total of 2.183 billion yuan in dividends since its A-share listing, with 1.245 billion yuan distributed over the last three years [3] Financing and Trading Activity - On October 20, Jiuzhou Pharmaceutical had a net financing purchase of 1.664 million yuan, with a total financing balance of 528 million yuan, representing 3.14% of its market capitalization [1] - The company’s financing balance is above the 90th percentile of the past year, indicating a high level of investor interest [1] - In terms of securities lending, Jiuzhou Pharmaceutical had a low short-selling balance of 2.3136 million yuan, which is below the 50th percentile of the past year, suggesting limited bearish sentiment [1] Shareholder and Institutional Holdings - As of September 30, the number of Jiuzhou Pharmaceutical shareholders increased to 59,200, a rise of 10.22%, while the average number of shares held per shareholder decreased by 9.27% to 15,035 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 20.368 million shares, an increase of 7.8125 million shares from the previous period [3] - The sixth largest shareholder, China Europe Medical Health Mixed A, holds 17.403 million shares, up by 3.9767 million shares, while the seventh largest, Huabao CSI Medical ETF, reduced its holdings by 2.5629 million shares to 15.2225 million shares [3]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index declined by 3.65% during the reporting period, ranking 21st among 31 primary industries, underperforming the CSI 300 index which fell by 2.73% [4][16] - The valuation of the pharmaceutical and biotechnology industry as of October 17, 2025, is a PE (TTM overall method, excluding negative values) of 30.08x, down from 31.23x in the previous period, indicating a downward trend and below the average [4][21] - Key sub-industries include vaccines (55.76x), hospitals (39.64x), and medical devices (38.84x), with the lowest valuation in pharmaceutical circulation (14.29x) [4][21] - The report highlights significant innovations presented at the 2025 ESMO conference, indicating a shift in global oncology drug development from "single-agent breakthroughs" to "combination therapy strategies" [6][8] - The newly released regulations by the State Council aim to standardize clinical research pathways, promoting innovation while ensuring safety [7][25][26] Industry Overview - The report notes that 26 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 501 million yuan, while 4 companies increased their holdings by 519 million yuan [4] - The report emphasizes the importance of monitoring third-quarter earnings to validate the fundamentals of companies, particularly those with innovative product launches and significant performance improvements [8] Important Industry News - The approval of the first domestic PDE4 inhibitor by He Mei Pharmaceutical marks a significant milestone in the industry [6][34] - The approval of a new indication for GSK's recombinant shingles vaccine expands its application to adults at increased risk due to immunodeficiency [6][36] - The U.S. Senate passed a revised version of the Biosecurity Act, which continues to impose restrictions on certain Chinese biotechnology companies [6][44] - The collaboration between Bai Li Tian Heng and BMS on the iza-bren project has reached a milestone, triggering a payment of 250 million USD [6][47] - The IPO of Xuan Zhu Biotechnology on the Hong Kong Stock Exchange saw a significant oversubscription and a substantial increase in share price during the dark trading period [6][49]

Group 1: Institutional Research on Popular Companies - The top twenty companies with the highest number of institutional research visits in the past 30 days include Rongbai Technology, Jingzhida, Shouchuang Environmental Protection, World, and Jiufeng Energy [12] - In the last five days, the most researched companies were Dike Co., Jiuzhou Pharmaceutical, Aipeng Medical, Juzan Optoelectronics, and LiuGong [13] - Among the top twenty companies in the past 30 days, 11 had ten or more rating agencies, with Huafeng Measurement and Huichuan Technology expected to see significant growth in net profit for the first half of 2025 compared to 2024 [12] Group 2: Major Shareholder Increase in A-Share Companies - From October 13 to October 17, 2025, six A-share companies announced significant shareholder increases, with Luyin Investment and Beichen Industrial planning to increase their holdings by amounts exceeding 1% of the latest market value [17] - From January 1 to October 17, 2025, a total of 285 companies announced shareholder increases, with 81 having ten or more rating agencies, and 20 of these companies planning increases exceeding 1% of their latest market value [19] Group 3: A-Share Company Buyback Situation - From October 13 to October 17, 2025, 72 companies announced buyback progress, with 12 having ten or more rating agencies, and four companies expected to have buyback amounts exceeding 1% of their market value [24] - From January 1 to October 17, 2025, 1,768 companies announced buyback progress, with 383 having ten or more rating agencies, and 89 companies expected to have buyback amounts exceeding 1% of their market value [27]